Lexaria Announces Positive Final Results From Human Pilot Study #5

Core Viewpoint - Lexaria Bioscience Corp. is advancing its efforts to develop the world's first oral liraglutide product, following positive results from its Human Pilot Study 5 comparing oral DehydraTECH-liraglutide capsules to injected Saxenda branded liraglutide [1] Group 1 - The final results from Human Pilot Study 5 (GLP-1-H25-5) indicate a successful comparison between oral DHT-LIR capsules and injected SAX-LIR [1] - Richard Christopher, CEO of Lexaria, expressed satisfaction with the results of the study, highlighting the company's optimism regarding the findings [1]